A Phase III Trial Evaluating Iomab-B Prior to HCT in Relapsed/Refractory AML
Edward Agura, MD, Texas Oncology - Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, discusses the phase III SIERRA trial, which is an ongoing trial investigating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).
Edward Agura, MD, Texas Oncology - Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, discusses the phase III SIERRA trial, which is an ongoing trial investigating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).
The SIERRA trial is the first randomized phase III study comparing a transplant treatment using a radioiodinated antibody to ablate the marrow, compared to conventional chemotherapy, Agura explains. The study is specifically designed for patients who are over age 65 and have recurrent or relapsed AML. What makes this trial unique is that it allows older patients to undergo a transplant that is potentially curative, Agura says.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
